Harmaline

Harmaline

SCHEMBL29626541

COc1ccc2c3c([nH]c2c1)C(C)=NCC3

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 1.00
MEN1 O00255 7/20 1.00
KMT2A Q03164 7/20 1.00
CASP1 P29466 6/20 1.00
HTR7 P34969 6/20 1.00
MAPT P10636 6/20 1.00
CYP2D6 P10635 5/20 1.00
ALDH1A1 P00352 5/20 1.00
HPGD P15428 5/20 1.00
CASP7 P55210 5/20 1.00
HSD17B10 Q99714 5/20 1.00
CYP3A4 P08684 4/20 1.00
HTR2C P28335 4/20 1.00
TDP1 Q9NUW8 4/20 1.00
RECQL P46063 3/20 1.00
HTR2A P28223 3/20 1.00
HTR6 P50406 3/20 1.00
POLB P06746 3/20 1.00
GLA P06280 2/20 1.00
TSHR P16473 2/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Harmaline SCHEMBL199260 1.00 KDM4E (1.00) KDM4EMEN1KMT2ACASP1HTR7
Harmaline SCHEMBL1360259 0.99 KDM4E (0.97) KDM4EMEN1KMT2ACASP1HTR7
Harmaline SCHEMBL177545 0.97 KDM4E (1.00) KDM4EMEN1KMT2ACASP1HTR7
Harmaline SCHEMBL30055802 0.97 KDM4E (1.00) KDM4EMEN1KMT2ACASP1HTR7
Harmaline SCHEMBL31500129 0.91 KDM4E (0.83) KDM4EMEN1KMT2ACASP1HTR7
Harmaline SCHEMBL9481244 0.89 KDM4E (0.80) KDM4EMEN1KMT2ACASP1HTR7
SCHEMBL3877767 0.89 KDM4E (1.00) KDM4EMEN1KMT2ACASP1HTR7
Harmaline SCHEMBL28061967 0.89 KDM4E (0.78) KDM4EMEN1KMT2ACASP1HTR7
SCHEMBL1520427 0.85 KDM4E (0.74) KDM4EMEN1KMT2ACASP1HTR7
SCHEMBL28871756 0.83 KDM4E (0.70) KDM4EMEN1KMT2ACASP1HTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12263178-B2 Pharmaceutical compositions and methods POP TEST ONCOLOGY LLC (US) 2025-04-01 US claimed
EP-3946296-B9 EXTENDED RELEASE PHARMACEUTICAL FORMULATION DOUGLAS PHARMACEUTICALS LTD (NZ) 2024-12-25 EP claimed
EP-3946296-B1 EXTENDED RELEASE PHARMACEUTICAL FORMULATION DOUGLAS PHARMACEUTICALS LTD (NZ) 2024-05-01 EP claimed
US-20230142627-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS POP TEST ONCOLOGY LLC (US) 2023-05-11 US claimed
EP-2926119-B1 METHOD OF MARKING OF MATERIAL, MARKED MATERIAL AND METHOD FOR AUTHENTICATING A MATERIAL SICPA HOLDING SA (CH) 2023-02-22 EP claimed
EP-4313985-A2 HETEROCYCLIC COMPOUNDS AND THEIR USE Equinorm Ltd (FI) 2024-02-07 EP disclosed
CN-117412975-A Heterocyclic compounds and their use 伊科诺姆有限公司 2024-01-16 CN disclosed
CN-115836058-A Benzisoxazole derivatives 住友制药株式会社 2023-03-21 CN disclosed
WO-2022207979-A2 NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE EQUINORM LTD (FI) 2022-10-06 WO disclosed
US-20220169606-A1 COMPOSITIONS AND COMPOUNDS FOR BIOANALYSIS SMALL PHARMA LTD. (GB) 2022-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220169606-A1 COMPOSITIONS AND COMPOUNDS FOR BIOANALYSIS BDNF, NEFM, PSMB6 KDM4E 2655/4885MEN1 1182/4885KMT2A 2685/4885
US-20230142627-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS NR3C2, NR3C1, MC2R KDM4E 4329/4885MEN1 510/4885KMT2A 3356/4885
US-12263178-B2 Pharmaceutical compositions and methods NR3C2, NR3C1, MC2R KDM4E 4329/4885MEN1 510/4885KMT2A 3356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.